TY  - JOUR
AU  - Kis, Erika
AU  - Baltás, Eszter
AU  - Ócsai, Henriette
AU  - Csányi, Ildikó
AU  - Ottlakán, Aurél
AU  - Lázár, György ifj
AU  - Vass, Gábor
AU  - Ágoston, Dóra
AU  - Rózsa, Petra
AU  - Bottyán, Krisztina
AU  - Dalmády, Szandra
AU  - Nagy, András
AU  - Tóth-Molnár, Edit
AU  - Oláh, Judit Magdolna
TI  - Az elektrokemoterápia mérföldkövei [Milestones of electrochemotherapy]
JF  - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE
J2  - BVSZ
VL  - 99
PY  - 2023
IS  - 2
SP  - 116
EP  - 120
PG  - 5
SN  - 0006-7768
DO  - 10.7188/bvsz.2023.99.2.5
UR  - https://m2.mtmt.hu/api/publication/33928735
ID  - 33928735
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Ottlakán, Aurél
AU  - Lázár, György ifj
AU  - Hideghéty, Katalin
AU  - Kószó, Renáta Lilla
AU  - Deák , Bence
AU  - Nagy, András
AU  - Besenyi, Zsuzsanna
AU  - Bottyán, Krisztina
AU  - Vass, Gábor
AU  - Oláh, Judit Magdolna
AU  - Kis, Erika
TI  - Clinical considerations of bleomycin based electrochemotherapy with Variable Electrode Geometry electrodes for inoperable, deep-seated soft tissue sarcomas
JF  - BIOELECTROCHEMISTRY
J2  - BIOELECTROCHEMISTRY
VL  - 148
PY  - 2022
PG  - 9
SN  - 1567-5394
DO  - 10.1016/j.bioelechem.2022.108220
UR  - https://m2.mtmt.hu/api/publication/33041891
ID  - 33041891
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Ottlakán, Aurél
AU  - Lázár, György ifj
AU  - Oláh, Judit Magdolna
AU  - Hideghéty, Katalin
AU  - Kószó, Renáta Lilla
AU  - Deák , Bence
AU  - Nagy, András
AU  - Bottyán, Krisztina
AU  - Vass, Gábor
AU  - Kis, Erika
TI  - Bleomycinalapú elektrokemoterápia lágyrészszarkómák kezelésére Variable Electrode Geometry elektródák használatával
JF  - MAGYAR ONKOLÓGIA
J2  - MAGYAR ONKOLÓGIA
VL  - 65
PY  - 2021
IS  - Suppl. 1
SP  - 47
EP  - 47
PG  - 1
SN  - 0025-0244
UR  - https://m2.mtmt.hu/api/publication/32490909
ID  - 32490909
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Groselj, Ales
AU  - Bosnjak, Masa
AU  - Krzan, Mojca
AU  - Kosjek, Tina
AU  - Bottyán, Krisztina
AU  - Plesnik, Helena
AU  - Jamsek, Crt
AU  - Cemazar, Maja
AU  - Kis, Erika
AU  - Sersa, Gregor
TI  - Bleomycin Concentration in Patients’ Plasma and Tumors after Electrochemotherapy. A Study from InspECT Group
JF  - PHARMACEUTICS
J2  - PHARMACEUTICS
VL  - 13
PY  - 2021
IS  - 9
PG  - 12
SN  - 1999-4923
DO  - 10.3390/pharmaceutics13091324
UR  - https://m2.mtmt.hu/api/publication/32163636
ID  - 32163636
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Dalmády, Szandra
AU  - Csoma, Zsanett
AU  - Besenyi, Zsuzsanna
AU  - Bottyán, Krisztina
AU  - Oláh, Judit Magdolna
AU  - Kemény, Lajos
AU  - Kis, Erika
TI  - New Treatment Option for Capillary Lymphangioma. Bleomycin-Based Electrochemotherapy of an Infant [Case Report]
TS  - Bleomycin-Based Electrochemotherapy of an Infant [Case Report]
JF  - PEDIATRICS
J2  - PEDIATRICS
VL  - 146
PY  - 2020
IS  - 6
PG  - 6
SN  - 0031-4005
DO  - 10.1542/peds.2020-0566
UR  - https://m2.mtmt.hu/api/publication/31787768
ID  - 31787768
N1  - Szövegében 3 oldalnál hosszabb Case Report, ezért besorolása szakcikk az MTA V. Osztályának ajánlása alapján (csonkap5, SZTE admin5)
AB  - The treatment of microcystic and combined lymphangiomas, especially in the head and neck region, is still a challenge because the lymphangiomas do not respond to conventional therapies and their recurrence rate is high, regardless of the treatment choice. Complete surgical resection is the main treatment of lymphangiomas, but because of localization perioperative complications, such as bleeding, neural damage and airway obstruction are common disadvantages of this method. Bleomycin-based sclerotherapy is another common therapeutic approach, in which the lymphocysts are aspirated, and 25% to 50% of their volumes are replaced with a sclerotisant drug. This is an effective treatment in cases in which the vessels are large enough for an intravascular or intracystic injection, but because of the small size of vessels and cysts, the microcystic and combined lymphangiomas are not suitable for sclerotherapy. Delivery of drugs for treating sclerosis to endothelial cells can be achieved by electroporation (electrochemotherapy), even for capillary malformations. A congenital, rapidly growing combined lymphangioma of the left cervicofacial region was treated with one session of bleomycin-based electrochemotherapy. Seven months after treatment, the growth-corrected target volume decrease was 63% and the dislocation of the trachea and blood vessels previously observed had ceased. We suggest that bleomycin-based electrochemotherapy is a feasible alternative treatment option for capillary malformations.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bottyán, Krisztina
AU  - Gaál, Magdolna
TI  - Botulinum toxin kezelés az esztétikában [Botulinum toxin treatment in aesthetic medicine]
JF  - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE
J2  - BVSZ
VL  - 96
PY  - 2020
IS  - 3
SP  - 128
EP  - 134
PG  - 7
SN  - 0006-7768
DO  - 10.7188/bvsz.2020.96.3.2
UR  - https://m2.mtmt.hu/api/publication/31538357
ID  - 31538357
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bottyán, Krisztina
AU  - Dalmády, Szandra
AU  - Kemény, Lajos
AU  - Csoma, Zsanett
TI  - „3 az 1-ben”: atópia, alopecia és psoriasis előfordulása egy gyermekben. [esetismertetés]
TS  - [esetismertetés]
JF  - GYERMEKORVOS TOVÁBBKÉPZÉS
J2  - GYERMEKORVOS TOVÁBBKÉPZÉS
VL  - 19
PY  - 2020
IS  - 3
SP  - 61
EP  - 64
PG  - 4
SN  - 1589-0309
UR  - https://m2.mtmt.hu/api/publication/31537868
ID  - 31537868
N1  - Nincs jelölve levelező szerzőség a közleményen. (TP SZTE admin5)
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Campana, Luca G.
AU  - Kis, Erika
AU  - Bottyán, Krisztina
AU  - Orlando, Antonio
AU  - de Terlizzi, Francesca
AU  - Mitsala, Grammatiki
AU  - Careri, Rosanna
AU  - Curatolo, Pietro
AU  - Snoj, Marko
AU  - Sersa, Gregor
AU  - Valpione, Sara
AU  - Quaglino, Pietro
AU  - Mowatt, David
AU  - Brizio, Matteo
AU  - Schepler, Hadrian
TI  - Electrochemotherapy for advanced cutaneous angiosarcoma: A European register-based cohort study from the International Network for Sharing Practices of electrochemotherapy (InspECT)
JF  - INTERNATIONAL JOURNAL OF SURGERY
J2  - INT J SURG
VL  - 72
PY  - 2019
SP  - 34
EP  - 42
PG  - 9
SN  - 1743-9191
DO  - 10.1016/j.ijsu.2019.10.013
UR  - https://m2.mtmt.hu/api/publication/31094270
ID  - 31094270
AB  - Background: Cutaneous angiosarcoma (cAS) is a highly aggressive malignancy that challenges the radicality of surgical treatment. Electrochemotherapy (ECT), a skin-directed treatment based on cytotoxic chemotherapy combined with local electric pulses, may be an intraoperative adjunct and a new opportunity in the therapeutic strategy. This cohort study reports the experience with ECT as an option.Methods: Data on patients with locally-advanced/metastatic cAS who underwent ECT between October 2013 and October 2018 at eight European centres were prospectively submitted to the InspECT (International network for sharing practices of ECT) register. Patients received therapy according to the European Standard Operating Procedures of ECT (ESOPE). Treatment feasibility was assessed based on tumour coverage with electrodes and recorded tissue current; treatment toxicity and tumour response were graded according to CTCAE v5.0 and RECIST v1.1 criteria, respectively; patient-reported outcomes (PRO) were evaluated using a visual analogue score (VAS) for pain, acceptance of retreatment and the EQ-5D questionnaire.Results: We enrolled 20 patients with advanced cAS in the scalp/face (n = 7), breast/trunk (n = 10) or limbs (n = 3). Target tumours (n = 51) had a median size of 2.3 cm (range, 1-20). We administered 24 ECT courses using 1-4 cm treatment safety margin around tumours. In five patients, ECT was combined/sequenced with surgery. Median tissue current was 3 A (range, 1.5-10), tumour margins coverage rate was 75% (15/20 patients). The objective response rate (ORR) was 80% (complete, 40%). Grade-3 toxicity included skin ulceration (15%) and pain (10%), with no significant change of PRO scores. Bleeding control was achieved in 13/14 patients with ulcerated tumours. With a median overall survival of 12.5 months, the local progression-free survival (LPFS) was 10.9 months.Conclusion: ECT produces sustained response rate with minimal side effects and should be considered an option for advanced cAS. Palliative benefits include patient tolerability, local haemostasis and durable local control. Definition of optimal timing, treatment safety margins and combination with surgery need further investigation.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Rózsa, Petra
AU  - Bottyán, Krisztina
AU  - Baltás, Eszter
AU  - Oláh, Judit Magdolna
AU  - Kemény, Lajos
AU  - Kis, Erika
TI  - Elektrokemoterápiával kezelt betegek életminőségének változása
JF  - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE
J2  - BVSZ
VL  - 95
PY  - 2019
IS  - 6
SP  - 284
EP  - 284
PG  - 1
SN  - 0006-7768
UR  - https://m2.mtmt.hu/api/publication/31068193
ID  - 31068193
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Bottyán, Krisztina
TI  - Cutan angiosarcoma elektrokemoterápiás kezelése az arc és a skalp területén
JF  - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE
J2  - BVSZ
VL  - 95
PY  - 2019
IS  - 6
SP  - 254
EP  - 254
PG  - 1
SN  - 0006-7768
UR  - https://m2.mtmt.hu/api/publication/31068085
ID  - 31068085
LA  - Hungarian
DB  - MTMT
ER  -